Email Alert RSS
Volume 1 Issue 2
Oct.  2010
Turn off MathJax
Article Contents
Abstract
References
Related Articles
Xiao-hong NING, Yu-zhou WANG, Zhao SUN, Ji LI, Yan-ping ZHOU, Chun-mei BAI. Role of ERCC1 Expression in Predicting the Outcome of Platinum-based Chemotherapy in Patients with End-stage Non-small-cell Lung Cancer[J]. Medical Journal of Peking Union Medical College Hospital, 2010, 1(2): 155-159.
Citation: Xiao-hong NING, Yu-zhou WANG, Zhao SUN, Ji LI, Yan-ping ZHOU, Chun-mei BAI. Role of ERCC1 Expression in Predicting the Outcome of Platinum-based Chemotherapy in Patients with End-stage Non-small-cell Lung Cancer[J]. Medical Journal of Peking Union Medical College Hospital, 2010, 1(2): 155-159.
shu

Role of ERCC1 Expression in Predicting the Outcome of Platinum-based Chemotherapy in Patients with End-stage Non-small-cell Lung Cancer

  • 1.

    Department of Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China

  • 2.

    Department of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China

More Information
  • Corresponding author:

    WANG Yu-zhou Tel:010-88068315, E-mail:wangyuzhou@hotmail.com

  • Received Date: August 22, 2010
  • Issue Publish Date: October 29, 2010
    Graphical Abstract
    • Abstract
  •   Objective  To explore the role of expression of excision repair cross-complementation group 1 (ERCC1) in predicting the outcomes of platinum-based chemotherapy in patients with end-stage non-small-cell lung cancer.
      Methods  The expression of ERCC1 was detected with immunohistochemical methods in paraffin-embeded tumor specimens obtained from 39 patients with chemo-naive non-small-cell lung cancer. The relationship between ERCC1 expression and the response rate of platinum-based chemotherapy as well as its possible values in predicting overall survival (OS) and time to progression (TTP) were analyzed.
      Results  ERCC1 was highly expressed in 39 tumors (56.4%). The expression of ERCC1 showed no association with gender, age, pathologic type, grade of differentiation, smoking history, and smoking index. The response rate of platinum-based chemotherapy was significantly higher in patients with low ERCC1 expression (P < 0.05). Furthermore, ERCC1 expression had no notable influence on OS and TTP.
      Conclusion  The expression of ERCC1 in lung tumor may be useful in predicting the effectiveness of platinum-based chemotherapy for end-stage non-small-cell lung cancer.
    • FullText(HTML)
    • References (14)
  • [1]
    Schiller JH, Harrington D, Belani CP, et al.Eastern Cooperative Oncology Group.Comparison of four chemotherapy regimens for advanced non small cell lung cancer[J]. N Engl J Med, 2002, 346:92-98. DOI: 10.1056/NEJMoa011954
    [2]
    Soria JC.ERCC1-tailored chemotherapy in lung cancer:the first prospective randomized trial[J]. J Clin Oncol, 2007, 25:2648-2649. DOI: 10.1200/JCO.2007.11.3167
    [3]
    Hwang IG, Ahn MJ, Park BB, et al.ERCC1 expression as a prognostic markerin N2 (+) nonsmall-cell lung cancer patients treated with platinum-based neoadjuvant concurrent chemoradiotherapy[J]. Cancer, 2008, 113:1379-1386. DOI: 10.1002/cncr.23693
    [4]
    Azuma K, Sasada T, Kawahara A, et al. Expression of ERCC1 and class Ⅲ beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel[J]. Lung Cancer, 2009, 64:326-333. DOI: 10.1016/j.lungcan.2008.09.002
    [5]
    Chen S, Zhang J, Wang R, et al.The platinum-based treatments for advanced non-small cell lung cancer, is low/negative ERCC1 expression better than high/positive ERCC1 expression? A meta-analysis[J]. Lung Cancer, 2010-06-9 [Epubaheadofprint]. http://www.cancer.gov/cancertopics/types/lung.
    [6]
    Reynolds C, Obasaju C, Schell MJ, et al.Randomized phase Ⅲ trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancer[J]. J Clin Oncol, 2009, 27:5808-5815. DOI: 10.1200/JCO.2009.21.9766
    [7]
    Vilmar AC, Santoni-Rugiu E, Srensen JB.ERCC1 and histopathology in advanced NSCLC patients randomized in a large multicenter phase Ⅲ trial[J]. Ann Oncol, 2010, 21:1817-1824. DOI: 10.1093/annonc/mdq053
    [8]
    Planchard D, Domont J, Taranchon E, et al.The NER proteins are differentially expressed in ever smokers and in never smokers with lung adenocarcinoma[J]. Ann Oncol, 2009, 20:1257-1263. DOI: 10.1093/annonc/mdn785
    [9]
    Shimizu J, Horio Y, Osada H, et al.mRNA expression of RRM1, ERCC1 and ERCC2 is not associated with chemosensitivity to cisplatin, carboplatin and gemcitabine in human lung cancer cell lines[J]. Respirology, 2008, 13: 510-517. DOI: 10.1111/j.1440-1843.2008.01302.x
    [10]
    Booton R, Ward T, Ashcroft L, et al.ERCC1 mRNA expression is not associated with response and survival after platinum-based chemotherapy regimens in advanced non-small cell lung cancer.J Thorac Oncol, 2007, 2:902-906. DOI: 10.1097/JTO.0b013e318155a637
    [11]
    Lee KH, Min HS, Han SW, et al.ERCC1 expression by immunohistochemistry and EGFR mutations in resected non-small cell lung cancer[J]. Lung Cancer, 2008, 60:401- 407. DOI: 10.1016/j.lungcan.2007.10.014
    [12]
    Su C, Zhou S, Zhang L, et al.ERCC1, RRM1 and BRCA1 mRNA expression levels and clinical out come of advanced non-small cell lung cancer[J]. Med Oncol, 2010- 05-14 [Epubaheadofprint]. http://www.springer.com/medicine/oncology/journal/12032.
    [13]
    Yin J, Vogel U, Guo L, et al.Lack of association between DNA repair gene ERCC1 polymorphism and risk of lung cancer in a Chinese population[J]. Cancer Genet Cytogenet, 2006, 164:66-70. DOI: 10.1016/j.cancergencyto.2005.07.003
    [14]
    Yin Z, Su M, Li X, et al.ERCC2, ERCC1 polymorphisms and haplotypes, cooking oil fume and lung adenocarcinoma risk in Chinese non-smoking females[J]. J Exp Clin Cancer Res, 2009, 28:153. DOI: 10.1186/1756-9966-28-153
    • Related Articles

  • Related Articles

    [1]WANG Shuo, DENG Yuntian, PENG Huan, ZHANG Xiangfeng. Progress in the Treatment of Non-small Cell Lung Cancer with Immune Checkpoint Inhibitors[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(2): 409-415. DOI: 10.12290/xhyxzz.2022-0151
    [2]DAI Liyuan, SHI Yuankai, HAN Xiaohong. Advances in Dynamic Monitoring of Immune Checkpoint Inhibitors as the Prognostic Markers for Advanced Non-small Cell Lung Cancer[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(2): 287-295. DOI: 10.12290/xhyxzz.2021-0608
    [3]WU Li'na, GAO Yi, LI Wosong, LIU Yong, QIN Xiaosong. Application Value of Serum Kreb Von Den Lungen-6 in the Adjuvant Treatment of Lung Injury after Non-small Cell Lung Cancer Surgery[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(4): 496-502. DOI: 10.12290/xhyxzz.2021-0308
    [4]LI Guo-yu, HE Ming. Research Progress of Targeted Therapy at Rare Targets for Non-small Cell Lung Cancer[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(2): 268-274. DOI: 10.3969/j.issn.1674-9081.2020.00.019
    [5]Lei LIU, Jia-qi ZHANG, Gui-ge WANG, Cheng HUANG, Li LI, Nai-xin LIANG, Shan-qing LI. Fibroblast Growth Factor Receptor 1 in Non-small Cell Lung Cancer[J]. Medical Journal of Peking Union Medical College Hospital, 2019, 10(6): 666-672. DOI: 10.3969/j.issn.1674-9081.2019.06.020
    [6]Jia-qi ZHANG, Lei LIU, Gui-ge WANG, Wen-liang BAI, Shan-qing LI. Clinical Pathological Features and Prognosis of Non-small Cell Lung Cancer with Skip N2 Lymph Node Metastasis[J]. Medical Journal of Peking Union Medical College Hospital, 2019, 10(3): 272-277. DOI: 10.3969/j.issn.1674-9081.2019.03.015
    [7]Xiao-na JIN, Nai-xin LIANG, Meng-zhao WANG, Bing JIA, Xi-min SHI, Shan-qing LI, Fang LI, Fan WANG, Zhao-hui ZHU. Integrin Receptor Imaging 99mTc-3PRGD2 SPECT/CT in Diagnosis and Lymph Node Staging of Non-Small Cell Lung Cancer[J]. Medical Journal of Peking Union Medical College Hospital, 2016, 7(5): 327-333. DOI: 10.3969/j.issn.1674-9081.2016.05.002
    [8]Xiao-hua SHI, Sha-fei WU, Qing LING, Zhen HUO, Zhi-yong LIANG. Clinicopathological Features and Immunohistochemical Phenotypes of Adenoid Cystic Carcinoma of the Uterine Cervix[J]. Medical Journal of Peking Union Medical College Hospital, 2015, 6(3): 197-201. DOI: 10.3969/j.issn.1674-9081.2015.03.007
    [9]Nai-xin LIANG, Ya-xin LIU, Lei LIU, Shan-qing LI. Co-mutation of PIK3CA and Other Oncogenes in Patients with Non-small Cell Lung Cancer[J]. Medical Journal of Peking Union Medical College Hospital, 2015, 6(3): 186-190. DOI: 10.3969/j.issn.1674-9081.2015.03.005
    [10]Xiao-hua SHI, Zhi-yong LIANG, Huan-wen WU, Xin-yu REN, Tong-hua LIU. Effect of RNA Interference Plasmid on the Expression of Oncogene AKT2 in Pancreatic Cancer Cell Line Panc-1[J]. Medical Journal of Peking Union Medical College Hospital, 2012, 3(1): 102-108. DOI: 10.3969/j.issn.1674-9081.2012.01.021

Catalog

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (343) PDF downloads (16) Cited by()
    Related
    Links: National Health Commission of the People's Republic of China Chinese Academy of Medical Sciences(CAMS) AMLC Check CNKI Database CNKI Term Online Chinese General Practice
    Address：Room 302,Third Floor,Building 7, No. 1 Shuaifuyuan, Wangfujing, Dongcheng District, Beijing 100730, China
    Tel：010-69154261/4262
    E - mail：medj@pumch.cn mjpumch@126.com
    Copyright of website：Editorial Office of Medical Journal of Peking Union Medical College Hospital

    Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return
    x Close Forever Close